Medicines for obesity, diabetes, rare diseases, cancer, and women’s health feature among Clarivate’s annual round-up of 11 Drugs to Watch this year, but two of them far outstrip the others in sales potential.There are no prizes for guessing that the multibillion-dollar predictions go to GLP-1-based therapies for obesity and type 2 diabetes, given the class […]
